Literature DB >> 6142632

The susceptibility of BALB/C and other inbred mouse strains to Brugia pahangi.

R E Howells, E Devaney, G Smith, T Hedges.   

Abstract

The susceptibility of several strains of inbred mice to infection with the filarial worm Brugia pahangi has been examined. BALB/C, C57BL/10, C3H/He, 101, CBA/Ca mice, congenitally asplenic (DH/+) mice and their normal litter-mates (+/+) were each challenged by the intraperitoneal inoculation of 50 infective larvae. During the first four weeks of infection high (19-42%) larval recoveries were obtained from the CBA/Ca, BALB/C and Dh/+ mice but fewer than 10% of inoculated larvae were recovered from C3H/He, 101; C57BL/10 and +/+ mice. Larval growth rates in all mice were similar. BALB/C and Dh/+ mice only were examined later than four weeks after infection. The yield of adult worms from BALB/C was 7.5% at 16 weeks and from Dh/+ 4.2% at 21 weeks. Microfilariae were present in the peritoneal fluids but not the blood of some mice harbouring both adult male and female worms.

Entities:  

Mesh:

Year:  1983        PMID: 6142632

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  3 in total

1.  Effect of carrageenan on the resistance of congenitally athymic nude and normal BALB/c mice to infective larvae of Brugia malayi.

Authors:  U R Rao; A C Vickery; B H Kwa; J K Nayar; D Subrahmanyam
Journal:  Parasitol Res       Date:  1992       Impact factor: 2.289

2.  Attempts to Image the Early Inflammatory Response during Infection with the Lymphatic Filarial Nematode Brugia pahangi in a Mouse Model.

Authors:  Elmarie Myburgh; Ryan Ritchie; Amy Goundry; Kerry O'Neill; Francesco Marchesi; Eileen Devaney
Journal:  PLoS One       Date:  2016-12-16       Impact factor: 3.240

3.  Tetracyclines improve experimental lymphatic filariasis pathology by disrupting interleukin-4 receptor-mediated lymphangiogenesis.

Authors:  Julio Furlong-Silva; Stephen D Cross; Amy E Marriott; Nicolas Pionnier; John Archer; Andrew Steven; Stefan Schulte Merker; Matthias Mack; Young-Kwon Hong; Mark J Taylor; Joseph D Turner
Journal:  J Clin Invest       Date:  2021-03-01       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.